Price Target Changed • Apr 22
Price target increased by 7.8% to CHF7.81 Up from CHF7.24, the current price target is an average from 8 analysts. New target price is 12% above last closing price of CHF7.00. Stock is down 66% over the past year. The company is forecast to post a net loss per share of CHF1.59 next year compared to a net loss per share of CHF3.47 last year. Ankündigung • Apr 17
DocMorris AG, Annual General Meeting, May 12, 2026 DocMorris AG, Annual General Meeting, May 12, 2026, at 17:00 W. Europe Standard Time. Price Target Changed • Mar 23
Price target decreased by 12% to CHF7.49 Down from CHF8.48, the current price target is an average from 9 analysts. New target price is 86% above last closing price of CHF4.02. Stock is down 78% over the past year. The company is forecast to post a net loss per share of CHF1.64 next year compared to a net loss per share of CHF3.47 last year. Reported Earnings • Mar 19
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: CHF3.47 loss per share. Revenue: CHF1.13b (up 11% from FY 2024). Net loss: CHF134.4m (loss widened 38% from FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 41%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Consumer Retailing industry in Europe. New Risk • Feb 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swiss stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Shareholders have been substantially diluted in the past year (277% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CHF29m net loss in 3 years). Price Target Changed • Dec 11
Price target decreased by 23% to CHF9.38 Down from CHF12.15, the current price target is an average from 9 analysts. New target price is 62% above last closing price of CHF5.80. Stock is down 78% over the past year. The company is forecast to post a net loss per share of CHF2.32 next year compared to a net loss per share of CHF8.25 last year. Major Estimate Revision • Aug 26
Consensus EPS estimates upgraded to CHF2.50 loss, revenue downgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from CHF1.17b to CHF1.13b. 2025 losses expected to reduce from -CHF3.35 to -CHF2.50 per share. Consumer Retailing industry in Switzerland expected to see average net income growth of 26% next year. Consensus price target down from CHF14.28 to CHF12.98. Share price rose 4.9% to CHF7.11 over the past week. Price Target Changed • Aug 20
Price target decreased by 7.5% to CHF13.39 Down from CHF14.48, the current price target is an average from 10 analysts. New target price is 93% above last closing price of CHF6.93. Stock is down 84% over the past year. The company is forecast to post a net loss per share of CHF2.33 next year compared to a net loss per share of CHF8.25 last year. Reported Earnings • Aug 20
Second quarter 2025 earnings released: CHF0.78 loss per share (vs CHF0.81 loss in 2Q 2024) Second quarter 2025 results: CHF0.78 loss per share. Revenue: CHF265.2m (up 5.3% from 2Q 2024). Net loss: CHF36.3m (loss widened 25% from 2Q 2024). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Consumer Retailing industry in Europe. Price Target Changed • Jul 16
Price target decreased by 19% to CHF14.48 Down from CHF17.89, the current price target is an average from 10 analysts. New target price is 88% above last closing price of CHF7.70. Stock is down 83% over the past year. The company is forecast to post a net loss per share of CHF3.06 next year compared to a net loss per share of CHF8.25 last year. Major Estimate Revision • Jul 03
Consensus EPS estimates upgraded to CHF3.13 loss The consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -CHF3.85 per share to -CHF3.13 per share. Revenue forecast reaffirmed at CHF1.17b. Consumer Retailing industry in Switzerland expected to see average net income growth of 22% next year. Consensus price target down from CHF17.89 to CHF16.80. Share price rose 7.7% to CHF6.72 over the past week. Price Target Changed • Jun 06
Price target decreased by 9.5% to CHF18.01 Down from CHF19.92, the current price target is an average from 12 analysts. New target price is 137% above last closing price of CHF7.61. Stock is down 88% over the past year. The company is forecast to post a net loss per share of CHF4.19 next year compared to a net loss per share of CHF8.25 last year. Major Estimate Revision • May 27
Consensus EPS estimates upgraded to CHF4.92 loss The consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -CHF5.59 to -CHF4.92 per share. Revenue forecast steady at CHF1.16b. Consumer Retailing industry in Switzerland expected to see average net income growth of 22% next year. Consensus price target down from CHF28.82 to CHF19.92. Share price fell 17% to CHF8.94 over the past week. Price Target Changed • May 26
Price target decreased by 15% to CHF24.42 Down from CHF28.82, the current price target is an average from 10 analysts. New target price is 158% above last closing price of CHF9.45. Stock is down 86% over the past year. The company is forecast to post a net loss per share of CHF5.15 next year compared to a net loss per share of CHF8.25 last year. Ankündigung • May 23
DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million. DocMorris AG has completed a Follow-on Equity Offering in the amount of CHF 208.051043 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 36,182,790
Price\Range: CHF 5.75
Transaction Features: Rights Offering New Risk • May 22
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 285% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (285% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CHF26m net loss in 3 years). Ankündigung • May 22
DocMorris AG announced that it expects to receive funding from Pelion S.A. DocMorris AG announced that it will receive Funding from the new investor, Pelion S.A. for 9.68% stake in the company on May 20, 2025. The company will issue Price Target Changed • May 21
Price target decreased by 12% to CHF26.82 Down from CHF30.60, the current price target is an average from 10 analysts. New target price is 164% above last closing price of CHF10.17. Stock is down 84% over the past year. The company is forecast to post a net loss per share of CHF5.59 next year compared to a net loss per share of CHF8.25 last year. Major Estimate Revision • May 15
Consensus EPS estimates upgraded to CHF5.59 loss The consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -CHF6.51 to -CHF5.59 per share. Revenue forecast unchanged from CHF1.16b at last update. Consumer Retailing industry in Switzerland expected to see average net income growth of 17% next year. Consensus price target down from CHF30.60 to CHF28.82. Share price fell 53% to CHF9.45 over the past week. Reported Earnings • May 09
First quarter 2025 earnings released: CHF2.13 loss per share (vs CHF0.75 loss in 1Q 2024) First quarter 2025 results: CHF2.13 loss per share (further deteriorated from CHF0.75 loss in 1Q 2024). Revenue: CHF282.6m (up 14% from 1Q 2024). Net loss: CHF25.2m (loss widened 185% from 1Q 2024). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. Board Change • May 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Non-Executive Independent Director Rongrong Hu was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Price Target Changed • Apr 17
Price target decreased by 11% to CHF30.60 Down from CHF34.30, the current price target is an average from 10 analysts. New target price is 51% above last closing price of CHF20.30. Stock is down 78% over the past year. The company is forecast to post a net loss per share of CHF6.51 next year compared to a net loss per share of CHF8.25 last year. Ankündigung • Apr 15
DocMorris AG, Annual General Meeting, May 08, 2025 DocMorris AG, Annual General Meeting, May 08, 2025, at 17:00 W. Europe Standard Time. Ankündigung • Apr 11
DocMorris AG Provides Earnings Guidance for the Year 2025 DocMorris AG provided earnings guidance for the year 2025. For the year, the company expects external revenues growth of more than 10%. Reported Earnings • Mar 14
First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023) First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 14% p.a. on average during the next 4 years, compared to a 4.9% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Breakeven Date Change • Mar 13
No longer forecast to breakeven The 10 analysts covering DocMorris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF4.08m in 2027. New consensus forecast suggests the company will make a loss of CHF22.5m in 2027. Price Target Changed • Jan 13
Price target decreased by 14% to CHF40.50 Down from CHF46.92, the current price target is an average from 12 analysts. New target price is 135% above last closing price of CHF17.21. Stock is down 76% over the past year. The company is forecast to post a net loss per share of CHF7.69 next year compared to a net loss per share of CHF10.07 last year. Price Target Changed • Jan 06
Price target decreased by 9.6% to CHF43.92 Down from CHF48.58, the current price target is an average from 12 analysts. New target price is 133% above last closing price of CHF18.84. Stock is down 76% over the past year. The company is forecast to post a net loss per share of CHF7.69 next year compared to a net loss per share of CHF10.07 last year. Price Target Changed • Dec 09
Price target decreased by 7.5% to CHF48.58 Down from CHF52.50, the current price target is an average from 12 analysts. New target price is 87% above last closing price of CHF25.96. Stock is down 64% over the past year. The company is forecast to post a net loss per share of CHF7.65 next year compared to a net loss per share of CHF10.07 last year. Price Target Changed • Oct 07
Price target decreased by 9.9% to CHF60.50 Down from CHF67.17, the current price target is an average from 12 analysts. New target price is 93% above last closing price of CHF31.42. Stock is down 36% over the past year. The company is forecast to post a net loss per share of CHF7.62 next year compared to a net loss per share of CHF10.07 last year. Price Target Changed • Sep 16
Price target decreased by 9.1% to CHF70.92 Down from CHF78.00, the current price target is an average from 12 analysts. New target price is 91% above last closing price of CHF37.20. Stock is down 32% over the past year. The company is forecast to post a net loss per share of CHF7.46 next year compared to a net loss per share of CHF10.07 last year. Breakeven Date Change • Sep 11
No longer forecast to breakeven The 12 analysts covering DocMorris no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of CHF6.48m in 2026. New consensus forecast suggests the company will make a loss of CHF16.1m in 2026. Reported Earnings • Aug 23
First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023) First half 2024 results: CHF3.22 loss per share (improved from CHF4.99 loss in 1H 2023). Revenue: CHF496.3m (up 7.2% from 1H 2023). Net loss: CHF37.9m (loss narrowed 35% from 1H 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Breakeven Date Change • Aug 22 The 12 analysts covering DocMorris previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 38% per year to 2025. The company is expected to make a profit of CHF8.95m in 2026. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
New Risk • Aug 22
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF97m Forecast net loss in 3 years: CHF387k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.7% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF387k net loss in 3 years). Shareholders have been diluted in the past year (9.5% increase in shares outstanding). Price Target Changed • Jul 17
Price target decreased by 10% to CHF88.50 Down from CHF98.58, the current price target is an average from 12 analysts. New target price is 88% above last closing price of CHF47.18. Stock is down 3.4% over the past year. The company is forecast to post a net loss per share of CHF7.23 next year compared to a net loss per share of CHF10.07 last year. Ankündigung • Jun 20
DocMorris AG to Report Q3, 2025 Results on Oct 16, 2025 DocMorris AG announced that they will report Q3, 2025 results on Oct 16, 2025 New Risk • May 03
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.1% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.0% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-CHF115m). Shareholders have been diluted in the past year (8.1% increase in shares outstanding). Price Target Changed • Apr 18
Price target increased by 7.5% to CHF99.24 Up from CHF92.35, the current price target is an average from 12 analysts. New target price is 15% above last closing price of CHF86.20. Stock is up 127% over the past year. The company is forecast to post a net loss per share of CHF6.69 next year compared to a net loss per share of CHF10.07 last year. Price Target Changed • Apr 16
Price target increased by 7.4% to CHF95.49 Up from CHF88.91, the current price target is an average from 12 analysts. New target price is 8.6% above last closing price of CHF87.95. Stock is up 122% over the past year. The company is forecast to post a net loss per share of CHF6.56 next year compared to a net loss per share of CHF10.07 last year. Reported Earnings • Mar 24
Full year 2023 earnings released: CHF10.07 loss per share (vs CHF15.88 loss in FY 2022) Full year 2023 results: CHF10.07 loss per share (improved from CHF15.88 loss in FY 2022). Revenue: CHF976.4m (down 39% from FY 2022). Net loss: CHF117.6m (loss narrowed 31% from FY 2022). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Price Target Changed • Mar 22
Price target increased by 7.2% to CHF85.27 Up from CHF79.55, the current price target is an average from 11 analysts. New target price is approximately in line with last closing price of CHF84.90. Stock is up 133% over the past year. Price Target Changed • Mar 20
Price target increased by 7.9% to CHF84.09 Up from CHF77.92, the current price target is an average from 11 analysts. New target price is 5.6% above last closing price of CHF79.60. Stock is up 78% over the past year. The company is forecast to post a net loss per share of CHF5.64 next year compared to a net loss per share of CHF15.88 last year. Major Estimate Revision • Jan 19
Consensus EPS estimates fall by 27% The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -CHF4.58 to -CHF5.81 per share. Revenue forecast unchanged at CHF967.8m. Consumer Retailing industry in Switzerland expected to see average net income growth of 25% next year. Consensus price target of CHF77.92 unchanged from last update. Share price fell 3.4% to CHF72.90 over the past week. Major Estimate Revision • Jan 12
Consensus EPS estimates upgraded to CHF4.58 loss The consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -CHF6.15 to -CHF4.58 per share. Revenue forecast steady at CHF966.2m. Consumer Retailing industry in Switzerland expected to see average net income growth of 25% next year. Consensus price target up from CHF69.00 to CHF77.92. Share price rose 5.5% to CHF74.20 over the past week. Price Target Changed • Jan 09
Price target increased by 8.7% to CHF75.00 Up from CHF69.00, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of CHF78.50. Stock is up 145% over the past year. The company is forecast to post a net loss per share of CHF6.14 next year compared to a net loss per share of CHF15.88 last year. Price Target Changed • Jan 05
Price target increased by 12% to CHF72.33 Up from CHF64.58, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of CHF70.30. Stock is up 135% over the past year. The company is forecast to post a net loss per share of CHF6.14 next year compared to a net loss per share of CHF15.88 last year. Price Target Changed • Dec 20
Price target increased by 9.1% to CHF69.00 Up from CHF63.27, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of CHF67.00. Stock is up 150% over the past year. The company is forecast to post a net loss per share of CHF6.15 next year compared to a net loss per share of CHF15.88 last year. Major Estimate Revision • Nov 27
Consensus EPS estimates fall by 11% The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -CHF4.86 to -CHF5.38 per share. Revenue forecast unchanged at CHF965.1m. Consumer Retailing industry in Switzerland expected to see average net income growth of 28% next year. Consensus price target of CHF62.27 unchanged from last update. Share price was steady at CHF53.30 over the past week. Major Estimate Revision • Nov 23
Consensus EPS estimates upgraded to CHF3.46 loss The consensus outlook for fiscal year 2023 has been updated. 2023 losses forecast to reduce from -CHF4.86 to -CHF3.46 per share. Revenue forecast steady at CHF965.1m. Consumer Retailing industry in Switzerland expected to see average net income growth of 28% next year. Consensus price target of CHF62.27 unchanged from last update. Share price rose 4.5% to CHF51.10 over the past week. New Risk • Oct 10
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CHF146m Forecast net loss in 3 years: CHF852k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CHF852k net loss in 3 years). Share price has been volatile over the past 3 months (7.3% average weekly change). Price Target Changed • Sep 19
Price target increased by 10% to CHF64.86 Up from CHF58.75, the current price target is an average from 11 analysts. New target price is 18% above last closing price of CHF54.75. Stock is up 62% over the past year. The company is forecast to post a net loss per share of CHF5.17 next year compared to a net loss per share of CHF15.88 last year. Major Estimate Revision • Aug 24
Consensus EPS estimates upgraded to CHF3.21 loss, revenue downgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from CHF1.08b to CHF979.6m. 2023 losses expected to reduce from -CHF8.75 to -CHF3.21 per share. Consumer Retailing industry in Switzerland expected to see average net income growth of 27% next year. Consensus price target up from CHF51.90 to CHF58.75. Share price rose 16% to CHF63.05 over the past week. Price Target Changed • Aug 21
Price target increased by 10% to CHF57.33 Up from CHF52.08, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of CHF60.25. Stock is up 4.5% over the past year. The company is forecast to post a net loss per share of CHF1.64 next year compared to a net loss per share of CHF15.88 last year. Reported Earnings • Aug 20
First half 2023 earnings released: CHF4.99 loss per share (vs CHF8.05 loss in 1H 2022) First half 2023 results: CHF4.99 loss per share (improved from CHF8.05 loss in 1H 2022). Revenue: CHF463.0m (down 6.4% from 1H 2022). Net loss: CHF58.2m (loss narrowed 30% from 1H 2022). Revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Consumer Retailing industry in Europe. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings. Ankündigung • May 05
Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE). Medbase AG agreed to acquire Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023. The proceeds from the sale of approximately CHF 360 million in cash comprise a first tranche upon completion of the transaction, expected in the second quarter of 2023, and an earnout of CHF 47 million based on the achievement of Zur Rose Switzerland's 2023 EBITDA target, payable in the second quarter of 2024. Zur Rose Switzerland achieved revenue of CHF 687 million in 2022.The transaction is expected to close in the second quarter of 2023, subject to approval by the competition authority. As on April 28, 2023 Competition commission validated the transaction. Matthias Courvoisier, Olha Demianiuk, Yves Mauchle, Beau Visser, Roger Thomi, Bettina Klein, Victoria Brammer and Victoria Hotz of Baker & McKenzie (Zurich) acted as legal advisor to Zur Rose Group AG. Morgan Stanley (NYSE:MS) and Enqcor AG acted as financial advisor to Zur Rose Group AG (SWX:ROSE).Bär & Karrer Ltd. acted as legal advisor to Medbase AG .
Medbase AG completed the acquisition of Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on May 4, 2023. Medbase is taking over all the Zur Rose Group's operational units in Switzerland excluding land and properties with all employees. Ankündigung • Feb 03
Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE). Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023.Medbase AG completed the acquisition of Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE) on February 3, 2023. Price Target Changed • Jan 24
Price target decreased by 30% to CHF37.96 Down from CHF53.96, the current price target is an average from 12 analysts. New target price is 11% above last closing price of CHF34.24. Stock is down 80% over the past year. The company is forecast to post a net loss per share of CHF14.63 next year compared to a net loss per share of CHF23.40 last year. Price Target Changed • Oct 14
Price target decreased to CHF73.14 Down from CHF78.73, the current price target is an average from 11 analysts. New target price is 179% above last closing price of CHF26.22. Stock is down 93% over the past year. The company is forecast to post a net loss per share of CHF15.14 next year compared to a net loss per share of CHF23.40 last year. Price Target Changed • Oct 04
Price target decreased to CHF78.73 Down from CHF85.27, the current price target is an average from 11 analysts. New target price is 150% above last closing price of CHF31.44. Stock is down 92% over the past year. The company is forecast to post a net loss per share of CHF15.55 next year compared to a net loss per share of CHF23.40 last year. Ankündigung • Sep 22
Reade Griffith acquired an unknown minority stake in Zur Rose Group AG (SWX:ROSE). Reade Griffith acquired an unknown minority stake in Zur Rose Group AG (SWX:ROSE) on September 21, 2022.
Reade Griffith completed the acquisition of an unknown minority stake in Zur Rose Group AG (SWX:ROSE) on September 21, 2022. Price Target Changed • Aug 19
Price target decreased to CHF107 Down from CHF134, the current price target is an average from 10 analysts. New target price is 78% above last closing price of CHF59.85. Stock is down 82% over the past year. The company is forecast to post a net loss per share of CHF16.03 next year compared to a net loss per share of CHF23.40 last year. Reported Earnings • Aug 19
First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind First half 2022 results: CHF8.29 loss per share (down from CHF8.03 loss in 1H 2021). Revenue: CHF840.3m (flat on 1H 2021). Net loss: CHF86.1m (loss widened 12% from 1H 2021). Revenue missed analyst estimates by 9.0%. Earnings per share (EPS) exceeded analyst estimates by 11%. Over the next year, revenue is forecast to grow 15%, compared to a 7.6% growth forecast for the Consumer Retailing industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Price Target Changed • Aug 09
Price target decreased to CHF134 Down from CHF146, the current price target is an average from 10 analysts. New target price is 123% above last closing price of CHF59.85. Stock is down 84% over the past year. The company is forecast to post a net loss per share of CHF16.03 next year compared to a net loss per share of CHF23.40 last year. Price Target Changed • Jul 14
Price target decreased to CHF154 Down from CHF166, the current price target is an average from 11 analysts. New target price is 128% above last closing price of CHF67.70. Stock is down 79% over the past year. The company is forecast to post a net loss per share of CHF16.39 next year compared to a net loss per share of CHF23.40 last year. Ankündigung • Jun 01
Zur Rose Group AG Announces Resignation of Betül Susamis Unaran, Chief Strategy and Digital Officer and as Member of the Executive Board Zur Rose Group AG announced that Betül Susamis Unaran Chief Strategy and Digital Officer as well as member of the Executive Board, has decided to pursue new career paths and leave the Zur Rose Group. In her almost three-year tenure, Ms. Unaran has been instrumental in the successful positioning of the Zur Rose Group and its transformation into the European healthcare ecosystem. In particular, she shaped and drove the rebranding of the DocMorris umbrella brand as well as the development of Health Journeys for people with obesity and diabetes. The implementation of the ecosystem strategy will be driven forward in all areas of the Zur Rose Group. The development of strategic partnerships will continue under the leadership of Anouk Robert, Group Director Partnerships and Branding. Price Target Changed • May 12
Price target decreased to CHF197 Down from CHF228, the current price target is an average from 10 analysts. New target price is 75% above last closing price of CHF113. Stock is down 63% over the past year. The company is forecast to post a net loss per share of CHF15.50 next year compared to a net loss per share of CHF23.40 last year. Ankündigung • Apr 06
Zur Rose Group AG to Report First Half, 2022 Results on Aug 18, 2022 Zur Rose Group AG announced that they will report first half, 2022 results on Aug 18, 2022 Price Target Changed • Mar 21
Price target decreased to CHF281 Down from CHF313, the current price target is an average from 10 analysts. New target price is 98% above last closing price of CHF142. Stock is down 57% over the past year. The company is forecast to post a net loss per share of CHF18.89 next year compared to a net loss per share of CHF14.95 last year. Price Target Changed • Mar 07
Price target decreased to CHF303 Down from CHF327, the current price target is an average from 10 analysts. New target price is 117% above last closing price of CHF139. Stock is down 63% over the past year. The company is forecast to post a net loss per share of CHF18.65 next year compared to a net loss per share of CHF14.95 last year. Major Estimate Revision • Jan 13
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 revenue forecast increased from CHF1.71b to CHF1.74b. Forecast EPS reduced from -CHF16.32 to -CHF18.18 per share. Consumer Retailing industry in Switzerland expected to see average net income growth of 12% next year. Consensus price target of CHF362 unchanged from last update. Share price fell 12% to CHF202 over the past week. Price Target Changed • Jan 07
Price target decreased to CHF387 Down from CHF417, the current price target is an average from 8 analysts. New target price is 79% above last closing price of CHF216. Stock is down 26% over the past year. The company is forecast to post a net loss per share of CHF16.32 next year compared to a net loss per share of CHF14.95 last year. Price Target Changed • Dec 31
Price target decreased to CHF404 Down from CHF437, the current price target is an average from 8 analysts. New target price is 72% above last closing price of CHF236. Stock is down 17% over the past year. The company is forecast to post a net loss per share of CHF16.32 next year compared to a net loss per share of CHF14.95 last year.